Labels
Breast Cancers
(148)
Lung Cancers
(75)
Genitourinary Cancers
(73)
Gastrointestinal Cancers
(67)
Gynecological Cancers
(58)
Head and Neck Cancers
(50)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Thursday, 10 April 2014
Post-Authorization Activity Table (PAAT) for Istodax
The PAAT describes post-authorization activity for Istodax, a product which contains the medicinal ingredient romidepsin. Istodax (romidepsin for injection), an antineoplastic agent, is indicated for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one prior systemic therapy. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment